SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back




Title
: Conversations in Primary Care: March 2, 2019
Activity/Course #:
: 03.02.19CPC

Cost:
: Free
Release/Start Date:
: Mar 02 2019
Expiration Date:
: Mar 02 2019
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Providers
Format:
: Live Virtual Conferences
Estimated Time To Complete CME Activity:
: 6.0 hours
Credit(s):
: 5.0 AMA PRA Category I Credit(s)
5.0 AANP Contact hour(s) which includes 2.75 pharmacology hour(s)
Hardware/Software Requirements:

There is no registration fee for this CME live virtual conference!

March 2, 2019
Broadcast Live from Ft. Lauderdale, FL
Start Time: 9:00 am EST
 

Program Summary:

Join Dr. Gregg Sherman and Dr. Angela Golden and stay on track to fulfill your CME requirements from the comfort of your home. Utilizing an interactive, moderator led format, this program will present discussions with national thought leaders to help you hone your skills in the diagnosis and management of patients you are likely encountering in your practice. You will be able to interact with the faculty real-time to get your questions answered.

Learning Objectives:
At the conclusion of this program, participants should be able to:

  1. Describe the newer concepts in the pathophysiology of asthma and type 2 inflammation, and the implications of biologic therapies in the era of precision medicine; Implement tools for clinical assessment of asthma control and risk factors for poor asthma outcomes with an emphasis of identifying patients that are candidates for biologic therapy; Individualize treatment of patients with moderate-to-severe asthma using available therapies; Discuss the impact of comorbid conditions on asthma control and the evidence-based approach to their treatment
  2. Implement measurement-based tools for assessing and monitoring symptoms in patients with MDD; Individualize treatment of MDD based on patient presentation, symptom profile and side effects; Recognize when switching initial pharmacotherapy is appropriate; Incorporate shared decision-making strategies into the management of patients with MDD
  3. Recognize the pervasive nature and global impact of ADHD symptoms throughout the day; Describe the physical and psychologic morbidity and mortality associated with ADHD; Use ADHD assessment tools to aid in diagnosis, track, and measure changes in ADHD symptoms to optimize pharmacologic treatment, non-pharmacologic treatment, and symptom control throughout the day; Implement appropriate and individualized treatment regimens for patients with ADHD
  4. Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes; Discuss current guidelines and recommendations on the management of hyperlipidemia in high risk patients; Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk; Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss novel strategies to overcome them
  5. Recognize the risk for, and impact of hypoglycemia in patients with diabetes; Describe strategies for reducing the risk of glycemic variability; Understand effective SMBG vs. newer CGM in managing diabetes and reducing risk of dysglycemia/hypoglycemia; Differentiate between available insulin preparations and the effects on glycemic variability and hypoglycemic risk

Agenda*

9:00-9:05 AM

 

Welcome Remarks
Gregg Sherman, MD and Angela Golden, DNP, FNP-C, FAANP

9:05-10:05   Individualizing Asthma Care: Addressing Type 2 Inflammation
Nicola Alexander Hanania, MD, MS
Moderator Gregg Sherman, MD
10:05-10:10   Break
10:10-11:15
  Case Studies in MDD: Individualizing Care
Greg Mattingly, MD
Moderator Angela Golden, DNP, FNP-C, FAANP
11:15-11:20   Break
11:20-12:20 PM
  Improving Outcomes in ADHD: It Can be Done in Primary Care!
Greg Mattingly, MD
Moderator Gregg Sherman, MD
12:20-12:50

Lunch Break

12:50-1:50
  Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care
David Smith, MD
Moderator Angela Golden, DNP, FNP-C, FAANP
1:50-1:55   Break
1:55-2:55
  Optimizing Diabetes Care: Evolving Strategies for Safer Integration of Insulin Therapy
Mark Stolar, MD
Moderator Gregg Sherman, MD

2:55-3:00


Closing Remarks
Gregg Sherman, MD

* Subject to Change


Faculty
Nicola Alexander Hanania, MD, MS
Associate Professor
Director, Airways Clinical Research Center
Member, Vice Chair of Research Group
Department of Medicine
Baylor College of Medicine
Director, Asthma and COPD Clinic
Ben Taub Hospital
Houston, TX

Greg Mattingly, MD
Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
St. Louis, MO

David N. Smith, MD

Clinical Assistant Professor of Medicine
Yale University
Associate Professor of Medicine, Wingate University
Adjunct Professor at UNC Chapel Hill

Charlotte, NC

Mark Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL

Moderators
Angela Golden, DNP, FNP-C, FAANP
Owner, NP from Home, LLC dba NP Obesity Treatment Clinic
Assistant Professor (Ret), Northern Arizona University
Vice President, Arizona Nurse Practitioner Council
Past President, American Association of Nurse Practitioners
Munds Park, AZ

Gregg Sherman, MD

Chief Medical Officer
National Association for Continuing Education
Plantation, FL

Planning Committee
Sandy Bihlmeyer, M.Ed.
Senior Project Manager
National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP

Vice-President
National Association for Continuing Education

Plantation, FL

Daniela Hiedra
Activity Director
National Association for Continuing Education
Plantation, FL

Joshua F. Kilbridge
President and Creative Director
Kilbridge Associates
San Francisco, CA

Gregg Sherman, MD
Course Director
Chief Medical Officer
National Association for Continuing Education
Plantation, FL

Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 5.0 contact hours of continuing education, including 2.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Commercial Support
This activity is supported by educational funding provided by Amgen; an educational grant provided by Sanofi Genzyme and Regeneron Pharmaceuticals; an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck; and an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com. This educational activity is supported by an independent medical educational grant from Shire.